Alzheimer's Disease Cooperative Study

Alzheimer's Disease Cooperative Study. It is a major clinical research consortium established and funded by the National Institute on Aging, part of the National Institutes of Health. The consortium was created to facilitate the development and testing of new therapies for Alzheimer's disease through large-scale, collaborative clinical trials across numerous academic sites. Its work has been instrumental in advancing the understanding of disease progression and evaluating potential treatments from pharmacological interventions to lifestyle and caregiving strategies.

History and establishment

The consortium was formally established in 1991 under a cooperative agreement mechanism by the National Institute on Aging. Its creation was driven by the urgent need for a coordinated national effort to address the growing public health challenge of Alzheimer's disease, following increased congressional attention and funding. The founding principal investigator was renowned neurologist Leon Thal of the University of California, San Diego, who helped shape its collaborative ethos. Early guidance also came from leaders within the National Institutes of Health and advisors from institutions like the University of Pennsylvania and Johns Hopkins University School of Medicine.

Organizational structure and governance

The operational leadership has historically been centered at a coordinating center, first at the University of California, San Diego and later at the University of Southern California. Governance involves a steering committee composed of principal investigators from member sites, representatives from the National Institute on Aging, and members from the Food and Drug Administration. The network itself comprises dozens of performance sites at major academic medical centers and clinics across the United States and Canada, including the Mayo Clinic, Columbia University, and the University of Washington. Statistical and data management cores, often based at institutions like the Harvard T.H. Chan School of Public Health, support trial design and analysis.

Major clinical trials and research initiatives

The consortium has conducted numerous landmark studies across various therapeutic domains. Key pharmacological trials include the Vitamin E and donepezil study for mild cognitive impairment and the Homocysteine and B vitamins trial. It has also extensively tested putative disease-modifying agents like DHA and Curcumin. Significant non-pharmacological initiatives include the Dementia Care Study and research into biomarkers through projects like the Alzheimer's Disease Neuroimaging Initiative. Other notable trials have evaluated drugs such as Rofecoxib, Naproxen, Valproate, and Leuprolide for their effects on Alzheimer's disease progression or symptoms.

Impact on Alzheimer's disease research and treatment

The consortium's work has fundamentally shaped the modern clinical trial landscape for Alzheimer's disease. Its studies have provided definitive evidence on the ineffectiveness of several high-profile candidate treatments, steering research investment toward new pathways. The group has developed and validated critical assessment tools, such as the Alzheimer's Disease Assessment Scale and the Activities of Daily Living inventory, which are now global standards. Findings from trials like the PREVENTION study have informed clinical practice guidelines and public health recommendations. Its biomarker work has contributed to revised diagnostic criteria by organizations like the Alzheimer's Association.

Collaborations and funding

Primary funding is provided through the National Institute on Aging via the U.S. Department of Health and Human Services. The consortium frequently partners with pharmaceutical companies, including Pfizer, Eli Lilly and Company, and Janssen Pharmaceutica, for specific interventional trials. It maintains close collaborative ties with other major research networks such as the Alzheimer's Therapeutic Research Institute and the Dominantly Inherited Alzheimer Network. Additional partnerships exist with advocacy groups like the Alzheimer's Association and with federal agencies including the Centers for Medicare & Medicaid Services for health outcomes research.

Category:Medical research organizations Category:Alzheimer's disease research Category:National Institutes of Health